30 closest matches · ranked by relevance
Lymphoma, Non-Hodgkin · Lymphoma · Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants
Lymphoma
Primary: Assessment of Tumor Response — 30.3; 54.5 percentage of participants
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Contiguous Stage II Grade 1 Follicular Lymphoma · Contiguous Stage II Grade 2 Follicular Lymphoma · Contiguous Stage II Marginal Zone Lymphoma
Primary: Progression-free Survival — 92; 71; 83; 71 Kaplan-Meier estimated % of patients
Low-Grade Lymphoma
Primary: Number of Participants With Objective Response — 1; 2; 14; 6 Participants
Lymphoma, Non-Hodgkin · MALT Lymphoma
Primary: Objective Response Rate — .85 proportion of patients
Low-grade B Cell Non-Hodgkin's Lymphoma · Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated
Primary: Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC) — 67.8; 70.0; 68.1 percentage…
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Response Rate — 29 percentage of participants
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Lymphoma
Primary: Time to Rituximab Failure (TTRF) — 3.92; 4.32; 1.39; 4.83 years — p=0.33
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Confirmed Response, Including Participants With Complete Response (CR), Clinical Complete Response (CCR), and Partial Response (PR) — 72…
Non-Hodgkin's Lymphoma
Primary: Overall Response Rate (Complete Response and Partial Response) After Three Inductions Cycles of Treatment. — 71 percentage of patients
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
Recurrent Grade 1 Follicular Lymphoma · Recurrent Grade 2 Follicular Lymphoma · Recurrent Grade 3 Follicular Lymphoma
Primary: Response Rate — 11; 6 participants
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Unconfirmed Response (Complete Response or Partial Response) and Unconfirmed Complete Response — 437; 238 Participants
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With a Complete Remission (CR) or Partial Remission (PR) — 39.5 percentage of participants
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants
Grade 1 Follicular Lymphoma · Grade 2 Follicular Lymphoma · Grade 3a Follicular Lymphoma
Primary: Number of Dose-limiting Toxicity Assessed Using Common Terminology Criteria for Adverse Events Version 4.0 (Phase Ib) — 1; 0 Participants
Lymphoma
Primary: Complete Response Rate — 65 percentage of evaluable participants
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue · Nodal Marginal Zone B-cell Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Number of Dose-limiting Toxicity (DLT) Events of Ipilimumab Plus a Fixed Dose of SD-101 (1 mg/Week) — 0 Dose-limiting toxicity events
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Unconfirmed Response (Complete Response, Complete Response/Unconfirmed, or Partial Response), as Assessed by the Investigator — 30…
Non-Hodgkin's Lymphoma
Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients
Ann Arbor Stage III Grade 1 Follicular Lymphoma · Ann Arbor Stage III Grade 2 Follicular Lymphoma · Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma
Primary: Number of Participants With Best Overall Disease Response — 0; 56; 17; 8 Participants
Lymphomatoid Granulomatosis · Granulomatosis, Lymphomatoid · Non-Hodgkins Lymphoma
Primary: Overall Response Rate (ORR) — 53.45; 51.85; 57.14; 50.00 percentage of participants
Indolent Non-Hodgkin's Lymphoma · Follicular Lymphoma · Small Lymphocytic Lymphoma
Primary: Overall Safety of Idelalisib — 88.9; 27.8; 55.6; 83.3 percentage of participants
Lymphoma
Primary: Number of Subjects With Dose-limiting Toxicities — 0 Participants
Diffuse Large B-cell Lymphoma
Primary: Number of Participants With Local Control — 61 Participants